Admission: BiVictriX Therapeutics Plc (AIM)
BiVictriX Therapeutics Plc (BiVictriX) announced its successful IPO and admission to trading on AIM, raising £7.5 million.
BiVictriX has successfully raised gross proceeds of £7.5 million by way of a placing and subscription at a market capitalisation of approximately £13.2 million. The funds will enable BiVictriX to accelerate its growth and expedite the development and delivery of its next-generation, highly selective cancer therapeutics.
Founded in 2017, BiVictriX is a drug discovery and development company that is applying a novel approach, derived from frontline clinical experience from within the NHS, to create safer, more effective cancer therapeutics. BiVictriX has developed a proprietary platform and the resulting Bi-Cygni® therapeutics are uniquely selective for the specific cancers, potentially enabling higher dosing and more aggressive tumour eradication, while reducing life-threatening treatment-related side effects.
Crowe's role and team
Crowe acted as reporting accountant to the transaction, with our capital markets team led by Mitesh Patelia and Will Smith.
Client quote
"The Capital Markets team at Crowe provided great expertise and efficiency throughout the transaction, enabling us to meet tight deadlines for a successful listing onto AIM. This deal marks an important step to accelerate growth, in particular for the lead asset BVX001, an antibody-drug conjugate that has generated encouraging preclinical data compared to similar drugs already on the market, including potential anti-cancer activity”
Tiffany Thorn, Chief Executive Officer, BiVictriX Therapeutics Plc
